Cancer diagnostics company Pacific Edge (NZE:PEB, ASX:PEB) said tests processed at its laboratories in the three months to the end of September were 2% lower than the prior quarter at 7,045, according to a Wednesday filing with the Australian and New Zealand bourses.
Asia Pacific volumes rose 6.2% to 1,363 tests from 1,283 in fiscal Q1, reflecting increased volumes in New Zealand and small growth from Australia and Asian distributors, the filing stated.
Group test volumes for the half year fell 22% to 14,233 from 18,240 in the first half of fiscal 2024, according to the filing.
Pacific Edge shares fell past 4% in recent Wednesday trade in New Zealand.
Price (AUD): $0.16, Change: $-0.0070, Percent Change: -4.32%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。